Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$24.59M+751.32%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Aziz Mottiwala
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 461
- Beta
- 1.19
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -0.90
Financials
Revenue
$24.59M+751.3%Net Income
$-16.22MEBITDA
$-15.26MFree Cash Flow
$44.04MEPS (diluted)
$-0.39Shares Outstanding (diluted)
41.71M+118.7%Operating Expenses
$36.62MCash & Debt
$254.68MRevenue by Segment (annual)
$134.48MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $134.48M | $-38.94M | $-0.95 |
| 2024 | $139.93M | $-27.45M | $-0.71 |
| 2023 | $89.08M | $-48.61M | $-1.41 |
| 2022 | $49.01M | $-66.76M | $-2.41 |
| 2021 | $22.59M | $-48.69M | $-1.78 |
| 2020 | $14.68M | $27.57M | $0.18 |
| 2019 | $2.24M | $126.22M | $0.95 |
Valuation
RXSThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·3d ago·Neutral
RxSight, Inc. to Present at the Piper Sandler Healthcare Conference ALISO VIEJO, Calif., Nov. 19, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to present at the Piper Sandler 38th Annual Healthcare Conference on Tuesday, December 1, 2026, at 4:00 p.m. ET in New York City. A live webcast of the presentation and an archived replay will be available on the Company's investor relations website at https://investors.rxsight.com/.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
RxSight, Inc. (RXST) Q3 2026 Earnings Call Transcript RxSight, Inc. (RXST) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·19d ago·Neutral
What RxSight (RXST) Said on Its Q3 Earnings Call RxSight NASDAQ: RXST reported third-quarter revenue of $24.6 million, down 19% from $30.3 million a year earlier, as the company faced competitive pressure, seasonal effects and disruption tied to a commercial restructuring and sales-force expansion.
View source ↗ - Newszacks.com·19d ago·Negative
RxSight, Inc. (RXST) Reports Q3 Loss, Lags Revenue Estimates RxSight, Inc. (RXST) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.04 per share a year ago.
View source ↗ - Newsglobenewswire.com·30d ago·Neutral
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules ALISO VIEJO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on October 23, 2026, RxSight granted inducement stock options to purchase a total of 236,456 shares of RxSight's common stock to two new non-executive officer employees in connection with the commencement of their employment with RxSight. RxSight also agreed to grant inducement restricted stock units (RSUs) covering a …
View source ↗ - Newsglobenewswire.com·37d ago·Neutral
K2 Vision Has Been Recognized as the Highest-Volume Light Adjustable Lens practice in the world K2 Vision has performed 5,000+ Light Adjustable Lens procedures and is recognized by RxSight as the highest-volume LAL practice in the world. Learn more.
View source ↗ - Newsglobenewswire.com·88d ago·Neutral
RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. ET in Boston, Massachusetts. A live and archived webcast of the presentation will be available on the Company's investor relations website at https://investors.rxsight.com/.
View source ↗
Earnings
Wed, Feb 24(in 3 months)
Consensus estimate $0.25 per share
Typical surprise +7.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$-0.39 vs $-0.31miss
- Wed, Aug 5$-0.29 vs $-0.33beat
- Wed, May 6$-0.38 vs $-0.30miss
- Wed, Feb 25$-0.22 vs $-0.33beat
- Wed, Nov 5$-0.24 vs $-0.34beat
- Thu, Aug 7$-0.29 vs $-0.25miss
Estimates and results for RXST via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RXST officers and directors.
- Bought
- —
- Sold
- $118k
0 trades
4 trades
- Kurtz Ronald M Mdsold
- Wilterding Marksold
- Goldshleger Ilyasold
- Weinberg Ericsold
96 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RXST.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
